Accueil › Myélome multiple › New York › Queens
Essais cliniques pour Myélome multiple à Queens, NY
20 études pour Myélome multiple recherchent des participants dans et autour de Queens (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Recrutement en coursPhase 2
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · à 13 mi
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 3
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola · à 11 mi
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Recrutement en coursPhase 3
- NYU Winthrop, Mineola · à 11 mi
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Recrutement en coursPhase 3
- Northwell Health Cancer Institute, Lake Success · à 9 mi
- NYU Langone Hospital Long Island, Mineola · à 11 mi
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Recrutement en coursPhase 3
- MSK Nassau, Uniondale · à 13 mi
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Recrutement en coursPhase 2
- Queens Cancer Center, Rego Park · à 3 mi
- Cohen Children's Medical Center, New Hyde Park · à 9 mi
- Northwell Health Monter Cancer Center, Lake Success · à 9 mi
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Recrutement en coursPhase 2
- Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale · à 13 mi
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Recrutement en coursPhase 3
- Long Island Jewish Medical Center, New Hyde Park · à 9 mi
- Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success · à 9 mi
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Recrutement en coursPhase 3
- MSK Nassau, Uniondale · à 13 mi
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Recrutement en coursPhase 1
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · à 13 mi
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Recrutement en coursPhase 3
- Research Site, New Hyde Park · à 9 mi
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Recrutement en coursÉtude observationnelle
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre · à 10 mi
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Recrutement en coursPhase 1/2
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · à 13 mi
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Recrutement en coursPhase 2
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · à 13 mi
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Recrutement en coursPhase 2
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · à 13 mi
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Recrutement en coursPhase 1/2
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola · à 11 mi
A Dietary Study for People With Multiple Myeloma
Recrutement en cours
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · à 13 mi
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Recrutement en coursPhase 2
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale · à 13 mi
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Memorial Sloan Kettering Rockville, Rockville Centre · à 10 mi
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Recrutement en cours
- Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale · à 13 mi
Essais pour Myélome multiple dans d'autres villes
- New York City, NY60 études
- Boston, MA42 études
- Atlanta, GA41 études
- Houston, TX38 études
- Durham, NC37 études
- Nashville, TN32 études
- Denver, CO27 études
- Rochester, MN24 études
- St. Louis, MO24 études
- Columbus, OH24 études
- Baldwin Park, CA23 études
- Chicago, IL22 études
Autres études à Queens
- Cancer du sein63 études
- Cancer du poumon non à petites cellules49 études
- Cancer colorectal31 études
- Cancer métastatique28 études
- Cancer de l'ovaire28 études
- Cancer de la prostate27 études
- Cancer (tous types)26 études
- Cancer de l'endomètre25 études
- Cancer du poumon22 études
- Leucémie aiguë myéloïde21 études
- Carcinome épidermoïde de la tête et du cou20 études
- Cancer du pancréas20 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.